Skip to content
Search

Latest Stories

Pharmacy Supervision Practice Group provides recommendations to DHSC to reframe legislation for community pharmacy

Pharmacy Supervision Practice Group, an organisations from across the community pharmacy sector, who have come together to look into the future “supervision” in community pharmacy, have published their final report.

Over the course of nine collaborative and positive workshop-style discussions the Supervision Practice Group aimed to provide recommendations to reframe legislation, regulation and professional standards and guidance to achieve a new vision for community pharmacy.


The group have produced a report which makes several recommendations on the subjects of:

• the legislation relating to “supervision”;

• the temporary absence of the RP from the pharmacy;

• delegation;

• the preparation and assembly of medicines when the RP is not signed in.

The group have provided recommendations on which the Department of and Social Care and the regulators can draft specifically worded revisions to legislation and regulatory standards. These specific legislative and regulatory changes that are proposed by government and regulators will be subject to a full consultation process.

Professional standards and guidance can then be updated to reflect these changes and provide further support to pharmacists and pharmacy technicians.

The group has encouraged all colleagues to read the whole document to understand discussions and reasoning for the recommendations.

Chair of the group, Dr Michael Twigg, Associate Professor of Primary Care Pharmacy, University of East Anglia and Head of Research Design and Evaluation, NHS Norfolk and Waveney said: “This report is a major step forward for community pharmacy and will enable the sector to work in new ways to support their patients and communities. It is a report that values the contribution of all members of the pharmacy team and provides a platform for the development of a more holistic model of care. I would like to thank all organisations for their commitment to this process and the honesty with which they have approached the discussions and their interaction with me. This report would not have been possible without this commitment to build a positive future for community pharmacy practice.”

AIMp Chief Executive Dr Leyla Hannbeck said: We have been a big advocate for seeking a level playing field for community pharmacists in line with our GP colleagues and this applies to the rules of supervision too. We will be responding to the government consultation in accordance with our vision for a robust, innovative and thriving community pharmacy sector with a skilled workforce that play a key role in the primary care.”

APTUK Vice President Nicola Stockman said: “The vision of community pharmacy practice described in the report will enhance patient access to pharmaceutical services, ensure high levels of patient safety, and enable further development of the community pharmacy team including pharmacy technicians. The consensus arrived at by the Supervision Practice Group should now inform a consultation by the Department of Health and Social Care which we look forward to engaging with.”

CCA Chief Executive Malcolm Harrison said: “All participants agreed on the need for change which is crucial to realising the increasingly clinical future expected of the sector. These changes provide the basis for the greatest evolution in pharmacy practice for 70 years. We want to thank Dr Michael Twigg for chairing the group and the Association of Optometrists for providing its secretariat. The CCA looks forward to responding to the upcoming DHSC consultation on this issue”.

NPA Chair Nick Kaye said: “There is consensus that the physical presence of a pharmacist in the pharmacy is a defining characteristic of community pharmacy – a principle which has been an anchor point for the NPA throughout these talks. We also all agree that changes to current arrangements are necessary to improve access and help pharmacists have the capacity to deliver more face-to-face clinical services. This report means that when the government proceeds to a full consultation on this matter it will have a clear sense of where the consensus sits within the sector.”

PDA Chairman Mark Koziol said: “We want to see pharmacists developing more comprehensive clinical relationships through the delivery of pharmaceutical care in the community pharmacy, to focus on the safety of medicines and to better support patients and the NHS. We have always believed that the physical presence of a pharmacist in a community pharmacy is fundamental to this vision.

"The report published today clearly puts forward a view that the physical presence of a pharmacist in a community pharmacy is essential in providing safe and effective patient care, and while there were differing views on the need for this to be specified in primary legislation, the general point about physical presence was agreed by all. We also welcome that the group agreed that the permitted 2-hour time period for absence should not change, and the PDA will seek to maintain that position. We will now be working with our members to feed into the formal consultation process when that is launched by the government.”

Pharmacy Forum NI Manager Julie Greenfield said: “The Pharmacy Forum NI believe the publication of this report creates a vision and approach that will inform the legislative and regulatory changes now required to deliver future innovation and service development within community pharmacy. Public and patient safety were foremost in our work in addition to enabling full and appropriate use of the skill mix and expertise of the whole pharmacy team.”

RPS President Professor Claire Anderson said: “On behalf of our members, we have been pressing for changes to Supervision legislation for many years. We were pleased to work collaboratively with other pharmacy organisation to feed our views into this statement. The output reflects the views of our Boards across Wales, Scotland and England. The RPS will continue to feed into the consultation process and will keep guiding the professions with trusted standards and advice to support the implementation of any future changes into practice.”

More For You

US-UK pharmaceutical trade concerns as Liberal Democrat MPs urge protection from Trump tariffs.

UK prime minster Sir Keir Starmer with US president Donald Trump

Pic credit: Getty images

Pharma sector needs protecting from Trump tariffs, warn MPs

A group of Liberal Democrat MPs have written to health secretary Wes Streeting urging him to protect the pharmaceutical industry from US president Donald Trump’s trade war.

The five ministers from Oxfordshire, Olly Glover, Layla Moran, Calum Miller, Charlie Maynard, and Freddie van Mierlo, have warned that Trump’s campaign to raise tariffs has already led to “catastrophic damage”.

Keep ReadingShow less
Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less